Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jo Shorthouse
With the impending European launch of Humira biosimilar adalimumab in October, Scrip talks to some of those in the region that have experience in launching commercially successful biosimilars about uptake, discounts and payer attitudes.
With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.
With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has opportunities for refreshment, both in the pipeline and the boardroom. But with generic competition battering down the company’s financial outlook, it may not be enough to bring the market along for the ride.
Jardiance growth offsets Micardis woes as the German major updates the industry on its H1.
Emerging Company Profile: With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light.
The contract services industry is reaping the rewards of a resilient biotech funding environment, re-accelerating growth in the sector.